The clinical-stage biotechnology company uses live, attenuated bacteria to secrete antigen/adjuvant fusion proteins that redirect the immune response to the cancer itself. Advaxis has over 15 distinct constructs in various stages of development, including ADXS-HPV being evaluated in four clinical trials for HPV-associated diseases. The company also collaborates with recognized centers of excellence to develop immunotherapies for cancer and infectious diseases. Advaxis' immunotherapy products include Axalimogene filolisbac (AXAL) for HPV-associated cancers and ADXS-PSA for prostate cancer associated with Prostate-Specific Antigen (PSA).